Loading clinical trials...
Loading clinical trials...
An Open-Label Phase 2 Study of Surufatinib in Patients With Neuroendocrine Tumours in Europe
Conditions
Interventions
Surufatinib
Locations
23
United States
University of Alabama, Birmingham (UAB)
Birmingham, Alabama, United States
University of California Irvine Medical Center UCIMC - H.H. Chao Comprehensive Digestive Disease Center CDDC
Orange, California, United States
Emory University, Winship Cancer Institute
Atlanta, Georgia, United States
Stony Brook Cancer Center
Stony Brook, New York, United States
Houston Methodist
Houston, Texas, United States
CHU Bordeaux
Pessac, France
Start Date
August 13, 2021
Primary Completion Date
September 6, 2024
Completion Date
October 15, 2024
Last Updated
July 25, 2025
NCT04649580
NCT02788565
NCT02075606
NCT03592940
Lead Sponsor
Hutchmed
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions